Andrews Marques Do Nascimento
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrews Marques Do Nascimento has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Cristiane Lyrio da Silva
Faculdade Multivix Vila Velha
1 shared publication - Dionisio Dubois Fillho
University Vila Velha
1 shared publication - Ewelyne Miranda de Lima
Universidade Vila Velha
1 shared publication - Girlandia Alexandre Brasil
Programa de Pós-Graduação em Assistência Farmacêutica, Universidade Vila Velha, Vila Velha, Brasil
1 shared publication - Mirian de Almeida Silva
University Vila Velha
1 shared publication - Nazaré Souza Bissoli
Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, Espirito Santo, Brazil
1 shared publication
Latest Publications
- Open Access
- 27 March 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (5)
Stanozolol induces ventricular dysfunction by decreasing phospholamban phosphorylation in heart tissue of LDLr-/- mice
Stanozolol is a steroid that causes lipid deposition in LDLr-/- mice, although the mechanism by which this dyslipidemia results in cardiac dysfunction is little understood. The aim of this study was to evaluate the effect of stanozolol on cardiac contractility and the participation of myocardial phospholamban (pPLB) phosphorylation in an atherosclerosis mouse model. LDL receptor knockout mice (LDLr-/-) were fed a standard chow diet and received weekly subcutaneous injections of either saline (control, C group) or 20 mg/kg stanozolol (S group). After 8 weeks, hemodynamic parameters were assessed in the left ventricle. The heart was collected, weighted for hypertrophy evaluation, and kept in formalin buffer for morphometric analysis (H&E) and collagen quantification (Picrossirius). Protein expression of PLB and its phosphorylated form (p-PLB) in the left ventricle was determined by western blot. We observed that stanozolol treatment favored cardiac hypertrophy and collagen deposition in heart tissue. Also, stanozolol induced left ventricle dysfunction, increasing PBL expression and decreasing the p-PLB/PLB ratio. Altogether, our data showed that stanozolol causes cardiac remodeling and ventricular dysfunction by decreasing PLB phosphorylation in the left ventricle of LDLr-/- mice.
- 27 March 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (5)
Open AccessStanozolol induces ventricular dysfunction by decreasing phospholamban phosphorylation in heart tissue of LDLr-/- mice
Stanozolol is a steroid that causes lipid deposition in LDLr-/- mice, although the mechanism by which this dyslipidemia results in cardiac dysfunction is little understood. The aim of this study was to evaluate the effect of stanozolol on cardiac contractility and the participation of myocardial phospholamban (pPLB) phosphorylation in an atherosclerosis mouse model. LDL receptor knockout mice (LDLr-/-) were fed a standard chow diet and received weekly subcutaneous injections of either saline (control, C group) or 20 mg/kg stanozolol (S group). After 8 weeks, hemodynamic parameters were assessed in the left ventricle. The heart was collected, weighted for hypertrophy evaluation, and kept in formalin buffer for morphometric analysis (H&E) and collagen quantification (Picrossirius). Protein expression of PLB and its phosphorylated form (p-PLB) in the left ventricle was determined by western blot. We observed that stanozolol treatment favored cardiac hypertrophy and collagen deposition in heart tissue. Also, stanozolol induced left ventricle dysfunction, increasing PBL expression and decreasing the p-PLB/PLB ratio. Altogether, our data showed that stanozolol causes cardiac remodeling and ventricular dysfunction by decreasing PLB phosphorylation in the left ventricle of LDLr-/- mice.